<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945308</url>
  </required_header>
  <id_info>
    <org_study_id>97/09</org_study_id>
    <nct_id>NCT00945308</nct_id>
  </id_info>
  <brief_title>Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients</brief_title>
  <acronym>ICE</acronym>
  <official_title>Effectiveness of Intracoronary Injection of Eptifibatide as Adjunctive Antiplatelet Therapy in Primary Coronary Intervention in Patients With ST Segment Elevation Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The achievement of high local concentration of Eptifibatide, a GP 2b3a inhibitor,via direct
      intracoronary injection, promotes (in vitro) clot disaggregation. It remains unclear if it is
      of superior benefit than the routine intravenous administration of these agents.

      In patients presenting with acute myocardial infarction, and undergoing primary coronary
      intervention, intracoronary administration of Eptifibatide may increase local drug
      concentration by several orders of magnitude and promote clot disaggregation with a minimal
      increase in systemic drug concentration, and in that way enhancing myocardial perfusion and
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized, prospectively, single blinded into one of two arms:1)intravenous
      administration of Eptifibatide and 2) intracoronary administration. The primary end-point
      will be the angiographic achievement of TIMI 3 flow at the infarct related artery and TIMI
      myocardial perfusion grade (blush) and the electrocardiographic surrogate of myocardial
      perfusion the ST segment resolution.

      The secondary end-points will be the occurrence of bleeding or hemorrhagic complication
      according to TIMI classification and the LVEF at one month compared with baseline
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary angiography</measure>
    <time_frame>At the time of the procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>90 min after the procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Eptifibatide (intracoronary)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eptifibatide (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide</intervention_name>
    <description>Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.</description>
    <arm_group_label>Eptifibatide (intracoronary)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide</intervention_name>
    <description>Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours</description>
    <arm_group_label>Eptifibatide (intravenous)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction candidate for primary coronary angioplasty, presenting
             within 12 hours of onset of pain and ability to clearly identified only one infarct
             related artery.

        Exclusion Criteria:

          -  Contraindications for antiplatelet therapy such as bleeding disorders,

          -  Thrombocytopenia,

          -  Severe uncontrolled hypertension,

          -  Recent stroke (&lt;6 months),

          -  Intracranial hemorrhage at any time

          -  Patients after recent major surgery (&lt;30 days),

          -  Previous myocardial infarction

          -  Previous revascularization either by CABG or PCI and 9)patients presented with
             cardiogenic shock.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Hendler, MD</last_name>
    <phone>+972526467757</phone>
    <email>ahendler@asaf.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alex Blatt, MD</last_name>
    <phone>+97257345906</phone>
    <email>alexb@asaf.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Beer Yakov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Hendler, MD</last_name>
      <phone>+9726467757</phone>
      <email>ahendler@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Alberto Hendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>July 23, 2009</last_update_submitted>
  <last_update_submitted_qc>July 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alberto Hendler MD</name_title>
    <organization>Assaf harofeh Medical Center</organization>
  </responsible_party>
  <keyword>Primary PCI</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Myocardial blush</keyword>
  <keyword>Primary coronary intervention in acute myocardial infarction</keyword>
  <keyword>focusing on the effect of the study drug on the immediate TIMI</keyword>
  <keyword>flow at the infarct related artery and on the myocardial</keyword>
  <keyword>perfusion evaluated by the TIMI myocardial perfusion grade or</keyword>
  <keyword>blush</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eptifibatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

